Effects of teneligliptin on glycemic control and bone metabolic markers in diabetic patients undergoing hemodialysis
Not Applicable
- Conditions
- diabetic patients undergoing hemodialysis
- Registration Number
- JPRN-UMIN000010780
- Lead Sponsor
- Diamond study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe liver dysfunction (AST more than 100 or ALT more than 100 IU/L) Patients with malignancy under medical treatmennt Patients with untreated diabetic retinopathy Patients terated with insulin injection Patients disqualified by doctor for any reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The improvement of glycemic control evaluated by area under the curve (AUC) using continuous glucose monitoring in the treatment with teneligliptin for 4 weeks
- Secondary Outcome Measures
Name Time Method The changes of glyated albumin (GA) and bone metabolic markers in the treatment with teneligliptin for 4 weeks